Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07SUG
|
||||
| Former ID |
DAP000983
|
||||
| Drug Name |
Busulfan
|
||||
| Synonyms |
Busulfano; Busulfanum; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; Citosulfan; Glyzophrol; Leucosulfan; Mablin; Methanesulfonic; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum; Mylecytan; Myleran; Mylerlan; Sulfabutin; Sulphabutin; Busulfan GlaxoSmithKline Brand; Busulfan Orphan Brand; Busulfan Wellcome; Busulfan Wellcome Brand; Glaxo Wellcome Brand of Busulfan; GlaxoSmithKline Brand of Busulfan; Myleran tablets; Orphan Brand of Busulfan; Tetramethylene bis[methanesulfonate]; Tetramethylene dimethane sulfonate; Tetramethylenester kyseliny methansulfonove; Tetramethylenester kyseliny methansulfonove[Czech]; Wellcome Brand of Busulfan; AN 33501; CB 2041; GT 2041; GT 41; X 149; Acid, tetramethylene ester; Alkylating agent: crosslinks guanine residues; Busulfan [INN:JAN]; Busulfano [INN-Spanish]; Busulfanum [INN-Latin]; MYLERAN (TN); Methanesulfonic acid, tetram ethylene ester; Methanesulfonic acid, tetramethylene ester; Myleran (TN); Sulfabutin (VAN); Tetramethylene bis(methanesulfonate); Tetramethylene {bis[methanesulfonate]}; Wellcome, Busulfan; C.B. 2041; G.T. 41; Myleran, Busulfex, Busulfan; Busulfan (JP15/USP/INN); Butane-1,4-diyl dimethanesulfonate; BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE); N-Butane-1,3-di(methylsulfonate); 1,4-BUTANEDIOL DIMETHANESULFONATE; 1,4-Bis(methanesulfonoxy)butane; 1,4-Bis(methanesulfonyloxy)butane; 1,4-Bis[methanesulfonoxy]butane; 1,4-Butanedi yl dimethanesulfonate; 1,4-Butanediol dimethanesulphonate; 1,4-Butanediol dimethylsulfonate; 1,4-Butanediol, dimethanesulfonate; 1,4-Butanediol, dimethanesulphonate; 1,4-Butanediyl dimethanesulfonate; 1,4-Di(methylsulfonoxy)butane; 1,4-Dimesyloxybutane; 1,4-Dimethane sulfonyl oxybutane; 1,4-Dimethanesulfonoxybutane; 1,4-Dimethanesulfonoxylbutane; 1,4-Dimethanesulfonyloxybutane; 1,4-Dimethanesulphonyloxybutane; 1,4-Dimethylsulfonoxybutane; 1,4-Dimethylsulfonyloxybutane; 1,{4-Bis[methanesulfonoxy]butane}; 4-((Methylsulfonyl)oxy)butyl methanesulfonate; 4-methylsulfonyloxybutyl methanesulfonate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C6H14O6S2
|
||||
| InChI |
InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
|
||||
| InChIKey |
COVZYZSDYWQREU-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 55-98-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9080, 67633, 219854, 3152242, 4652645, 7847314, 7978829, 8136888, 8149226, 8151654, 10321898, 11336022, 11361261, 11362926, 11365488, 11368050, 11371520, 11373837, 11376212, 11445992, 11446841, 11462233, 11483989, 11487883, 11490136, 11492074, 11493906, 11533211, 15221088, 17388889, 17389813, 24891664, 26611631, 26679765, 26747279, 26747280, 26747281, 26752840, 29221642, 46506234, 47365244, 47440312, 47440313, 48414081, 48415668, 48423740, 48424910, 48425335, 49648470, 49855504
|
||||
| ChEBI ID |
ChEBI:28901
|
||||
| SuperDrug ATC ID |
L01AB01
|
||||
| SuperDrug CAS ID |
cas=000055981
|
||||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Modulator | ||
| References | |||||
| Ref 538558 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020954. | ||||
| Ref 542143 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7136). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.